Matt Girgenti is an Assistant Professor of Psychiatry at Yale School of Medicine in the Division of Molecular Psychiatry and a member of the Wu Tsai Institute at Yale. He is also a VA-NCPTSD Research Scientist at the West Haven VA Medical Center. He received his doctoral degree at the University of Connecticut in molecular neuroscience. He completed his postdoctoral fellowship in Molecular Psychiatry at Yale followed by a VA Career Development fellowship in postmortem brain genomics. His early research focused on the epigenetic basis of schizophrenia using neural stem cells to demonstrate a role for the SCZ-risk gene ZNF804a as a gene transcription regulator. During his postdoc, his research focused on the cell-type-specific effects of rapid antidepressants, including ketamine and scopolamine using pharmacogenomic approaches. During his VA Career Development fellowship he worked on human postmortem studies focused on the functional genomics of neuropsychiatric disorders, specifically PTSD and major depression. He published the first genome-wide transcriptomic study of the human PTSD brain (Girgenti MJ, et al. 2021). His research now focuses on developing bioinformatic tools for integration of functional genomic data, such as epigenetic, transcriptomic, and proteomics from human postmortem brain to understand the molecular signatures of neuropsychiatric disease.